Advertisement
Canada markets closed

  • S&P/TSX

    21,947.41
    +124.19 (+0.57%)
     

  • S&P 500

    5,127.79
    +63.59 (+1.26%)
     

  • DOW

    38,675.68
    +450.02 (+1.18%)
     

  • CAD/USD

    0.7308
    -0.0005 (-0.07%)
     

  • CRUDE OIL

    77.99
    -0.96 (-1.22%)
     

  • Bitcoin CAD

    86,008.09
    +5,317.39 (+6.59%)
     

  • CMC Crypto 200

    1,359.11
    +82.14 (+6.43%)
     

  • GOLD FUTURES

    2,310.10
    +0.50 (+0.02%)
     

  • RUSSELL 2000

    2,035.72
    +19.61 (+0.97%)
     

  • 10-Yr Bond

    4.5000
    -0.0710 (-1.55%)
     

  • NASDAQ

    16,156.33
    +315.37 (+1.99%)
     

  • VOLATILITY

    13.49
    -1.19 (-8.11%)
     

  • FTSE

    8,213.49
    +41.34 (+0.51%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6787
    -0.0030 (-0.44%)
     

Will This Stock's Pain Be Medicare's Gain?

Dan Caplinger, The Motley Fool
·3 min read
Will This Stock's Pain Be Medicare's Gain?

The stock market has finally gotten some upward momentum, and Wall Street tried to carry it further into Wednesday's premarket session. S&P 500 (SNPINDEX: ^GSPC) futures had picked up 5 points to 4,710, and Nasdaq Composite (NASDAQINDEX: ^IXIC) futures had risen 35 points to 15,866. Biogen (NASDAQ: BIIB) was particularly noteworthy, because news about its treatment for Alzheimer's disease is setting up a potential financial battle between the biotech stock and the U.S. government's Medicare program.

Continue reading